Update and Challenges on HIV Infection in Romania in worldwide context
Main Article Content
Abstract
The issue to be addressed are the nowadays particularities and challenges of HIV infections in Romania and worldwide. Based on official data, other relevant information and our clinical experience, we have reviewed transmission, prevalence, screening, diagnostic and therapy of HIV Infection in Romania, identified problems, considered modern therapies and alternative management options, drawing logical conclusions and reflecting on possible solutions.
Introduction: The UN and EU proposed aim of eradicating HIV infection is worldwide hardly to attain. HIV virus primarily attacks T helper cells/ CD4+cells, which are T-lymphocyte cells with a critical role for immune system. If HIV infection goes untreated, the virus replicates in the host cells, destroying CD4+ cells. The remaining infected cells release virions, which infect other cells, leading to rapid spreading of the virus in the body (1). The loss of CD4+ T lymphocytes results in incapacity to develop a proper immune response against bacterial and fungal infections, like Tuberculosis, Pneumocystis or Cryptococcus, but also against viral infections like Herpes and against cancers, like lymphoma and Kaposi‘s Sarcom.
The CD4+count remains the most significant predictor for HIV disease progression. The normal CD4+count is >500/microL. When CD4+cells are lower than 200/microL, AIDS is diagnosed.
Method: Critical thinking methodology based on national and european statistics, focusing on problem analysis and options to resolve the problems.
Results: Romania has a very low incidence of new HIV cases comparative to EU, due to an effective national surveillance system, including early testing for risk groups. However, prevention through medication (PrEP) and new long-acting antiviral therapies are lacking and a lot of HIV-infected people are currently not under treatment.
Conclusions: Particular to Romanian HIV Infection is the long- living cohort of previous babies with HIV perinatally transmission, followed from nowadays predominant heterosexuell transmission. Another particularities are the late diagnosis to not at risk categories and the Tuberculosis co-infection.
More HIV Testing, inclusive to general practitioners and emergency-rooms, also self-testing, could make possible earlier diagnosis and therapy. Pre-exposure therapies (PrEP) and post- exposure prophylaxis (PEP) could be largely implemented, to prevent spriding of the virus.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Argesanu EM. Update on HIV infections in Romania. Roum Arch Microbiol Immunol. 81(2):143-44. April-June 2022.
3. Mardarescu M, Popa MI, Streinu- Cercel A. HIV/ AIDS in Romania- a short history and update. Roum Arch Microbiol Immunol. 2021;80(4):305-11. doi:10.54044/RAMI.2021.04.01.
4. HIV/AIDS Surveillance in Europe 2025-2024 data. www. ecdc.europa.eu. November 11, 2025.
5. Romania: Raising HIV awareness among young people. AIDS Action Europe interview with Baylor Foundation. www.aidsactioneurope.org/en/news/romania. Mai 17, 2023.
6. Universitätsspital Zürich. www.usz.ch/krankheit/hiv. August 31, 2020, actualised Mai 28, 2026.
7. Compartment for Monitoring and Evaluation of HIV/AIDS in Romania, statistical data. www.cnlas.ro/index.php/date-statistice. December 25, 2025.
8. Monitorul Oficial al Romaniei. Anexa la Hotărârea Guvernului nr. 1.440/2022 privind aprobarea Strategiei naționale pentru supravegherea, controlul și prevenirea cazurilor de infecție cu HIV/SIDA pentru perioada 2022—2030. [Annex to Government Decision no. 1440/2022 regarding approval of The National Strategy for surveillance, control and prevention of HIV infection/AIDS cases in the period 2022-2030]. https://www.cnlas.ro/images/doc/hg14402022.pdf. Accessed April 11, 2026.
9. Compartment for Monitoring and Evaluation of HIV/AIDS in Romania, time to act 2025- where are we? www.cnlas.ro/images/doc/2025/Romania-time-to-act.pdf. Accessed April 11, 2026.
10. Meintjes G, Maartens G. HIV- associated tuberculosis. N Engl J Med 2024; 391:343-55. doi: 10.1056/NEJMra2308181.
11. Smith JP, O‘Connor S, Date A, et al. Tuberculosis cases and deaths averted by PEPFAR, N Engl J Med 2026; 394:1655-56. doi: 10.1056/NEJMc2506284.
12. Saag MS. HIV infection-screening, diagnosis and treatment. N Engl J Med 2021;384(22): 2131-43. doi: 10.1056/NEJMcp1915826.
13. M‘pirah V, Mbomo S, Mintsa A, et al. Clinical diagnostic accuracy of the HIV rapid test ACCU- TELL anti -HIV 1+2 in sub- Saharan African region. BMC Infect Dis.2025Jul 1; 25:812.doi:10.1186/s12879-025-10496-3.
14. Compartment for Monitoring and Evaluation of HIV/ AIDS in Romania, surveillance of HIV. www.cnlas.ro/images/doc/31122020_eng.pdf. December 31, 2025.
15. InformatHIV Project. HIV testing and monitoring. https://informativ.ro/ro/de-unde-stiu-daca-am-hiv. Accessed April 11,2026.
16. Asociația Română Anti-SIDA. Checkpoint. www. arasnet.ro/checkpoint. Accessed April 11, 2026.
17. Compartment for Monitoring and Evaluation of HIV/AIDS. Future directions in HIV. https://www.cnlas.ro/images/doc/2024/HIV%20Future%20Directions.pdf. Accessed April 11, 2026.
18. The Elton John AIDS Foundation. Opportunity announcement – RADIAN 2.0 Equity Challenge Fund. www.eltonjohnaidsfoundation.org. Accessed April 11, 2026.
19. Integrating routine HIV screening into your practice. CDC-HIV-together campaign. www.cdc.gov. January 29, 2025.
20. Ratevosian J, Beyrer C, Chola M, et al. The New U.S. Global Health Strategy- A reset of America‘s health cooperation. N Engl J Med 2025; 393(22):2180-81.doi: 10.1056/NEJMp2514898.
21. Bekker L-G, Das M, Karim QA, et al. Twice - Yearly Lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med 2024; 391:1179-92. doi: 10.1056/NEJMoa2407001.
22. Segal-Maurer S, Dejesus E, Stellbrink H-J, et al. Capsid inhibition with Lenacapavir in multidrug- resistant HIV-1 infection. N Engl J Med 2022; 386(19): 1798-1802. doi: 10.1056/NEJMoa2115542.
23. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99. doi: 10.1056/NEJMoa1011205.
24. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021; 385(7):595-608. doi: 10.1056/NEJMoa2101016.
25. Linden JA. Care of the adult patient after sexual assault. N Engl J Med 2011; 365:834-35.
26. Jatt LP, Nyaradzo MM, Buchbinder SP, et al. An HIV vaccine in the era of twice-yearly Lenacapavir for PrEP- essential or irrelevant? N Engl J Med 2025; 392(16): 1561-63. doi: 10.1056/NEJMp2415893.
27. Rana AI, Zheng Lu, Castillo-Mancilla J, et al. Cabotegravir plus Rilpivirine for persons with HIV and adherence challenges. N Engl J Med 2026; 394(9): 858-71. doi:10.1056/NEJMoa2508228.
28. Kaposi-Sarkom, DGHO- Leitlinien. www.onkopedia.com . Accessed April 11,2026.